Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQD3524 in renal impairment
NCT06522945Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of colistimethate sodium in Gram-negative bacterial infection (6 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak Concentration at 24 hours, Area Under the Concentration-Time Curve at 24 hours and 7 more. Started Jul 2024; status: completed.
02
Drugs
colistimethate sodium
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT06522945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522945.